ADAM19 is a transmembrane metalloproteinase that plays crucial roles in extracellular matrix remodeling and cellular signaling through proteolytic cleavage of various substrates. The enzyme cleaves neuregulin-1 (NRG1), which must be processed to exert its pro-fibrotic function, and processes other growth factors including heparin-binding EGF and TNF-alpha 12. ADAM19 demonstrates tissue-specific expression patterns, being constitutively expressed in distal tubules and endothelial cells of normal kidneys, with de novo expression in proximal tubules during renal disease 3. The protein exhibits dual roles depending on developmental context - it is essential for embryonic development, cardiovascular morphogenesis, and neurogenesis, while also functioning as a neuroprotective alpha-secretase that processes amyloid precursor protein 2. However, ADAM19 becomes pathologically upregulated in various diseases. In systemic sclerosis, elevated ADAM19 promotes skin fibrosis by mediating NRG1 shedding and correlates with disease severity markers 1. The enzyme is overexpressed in multiple cancers including glioblastoma, retinoblastoma, and extrahepatic cholangiocarcinoma, where it associates with tumor invasiveness and poor prognosis 245. Additionally, ADAM19 is elevated in senescent chondrocytes and contributes to osteoarthritis pathology 6.